Nemes Laszlo/iStock via Getty Images
Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE:MRK) immunotherapy Keytruda, cut the risk of disease progression or death by 35% as a first-line option for an aggressive type of breast cancer.
Citing data
